The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Romanov D.V.

Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center

Sheyanov A.M.

Sechenov First Moscow State Medical University (Sechenov University)

Samsonova M.D.

Sechenov First Moscow State Medical University (Sechenov University)

Yuzbashyan P.G.

Sechenov First Moscow State Medical University (Sechenov University)

Nimodipine in treatment of bipolar disorder

Authors:

Romanov D.V., Sheyanov A.M., Samsonova M.D., Yuzbashyan P.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(12): 20‑26

DOI: 10.17116/jnevro202312312120

Views: 1779

Downloaded: 36

Download PDF (RU)
Contact the author
Table of contents

NIMODIPINE IN TREATMENT OF BIPOLAR DISORDER
NIMODIPINE IN TREATMENT OF BIPOLAR DISORDER

To cite this article:

Romanov DV, Sheyanov AM, Samsonova MD, Yuzbashyan PG. Nimodipine in treatment of bipolar disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(12):20‑26. (In Russ.)
https://doi.org/10.17116/jnevro202312312120

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Bipo­lar affe­ctive diso­rder occu­rring with psychopharmacotherapy-induced manic phases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):9-14
Features of cognitive impairment in bipo­lar affe­ctive diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):15-19
Growth factors PDGF-AA, PDGF-BB and BDNF as pote­ntial differentiating biomarkers of unipolar and bipo­lar depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):104-108
The gut microbiota in bipo­lar diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):28-33
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Comparative study of cognitive impairment in subgroups of bipo­lar affe­ctive diso­rder types I and II, occu­rring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11
Dyna­mics of the spectrum of geno­types of Listeria mono­cytogenes, which caused inva­sive listeriosis during the period of circulation of sars-cov-2 Omicron variants. Mole­cular Gene­tics, Microbiology and Viro­logy. 2024;(3):29-36
Glucocorticoid-resistant forms of endo­crine ophthalmopathy. Russian Annals of Ophthalmology. 2024;(6):125-130

The purpose of this review is to correlate current data on the molecular mechanisms of action of the drug Nimodipine with its clinical effects and applicability in mental disorders belonging to the spectrum of affective pathology. The article discusses the prospects for using the calcium channel blocker nimodipine as a method of both mono and combination therapy for bipolar disorders with various types of course. Nimodipine is a selective blocker of voltage-dependent calcium channels, a dihydropyridine derivative. By blocking L type calcium channels, it prevents the entry of calcium ions into the cell. Due to its pronounced ability to penetrate the blood-brain barrier, it has a selective effect on brain neurons and has a vasodilating, antihypertensive and normotimic effect. Nimodipine blocks LTCC channels in brain neurons, thereby influencing synaptic plasticity, transmitter release and excitation-transcription coupling, which makes it possible to influence various clinical conditions with pathology in the area of affect, including bipolar disorders with ultra-rapid cycling, and also, in cases with high resistance and intolerance to other mood stabilizers.

Keywords:

bipolar affective disorder
nimodipine
calcium antagonists
CACNA1C
LTCC
ultra-rapid cycling
continuous circular course
resistance
tolerance

Authors:

Romanov D.V.

Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center

Sheyanov A.M.

Sechenov First Moscow State Medical University (Sechenov University)

Samsonova M.D.

Sechenov First Moscow State Medical University (Sechenov University)

Yuzbashyan P.G.

Sechenov First Moscow State Medical University (Sechenov University)

Received:

01.11.2023

Accepted:

03.11.2023

List of references:

  1. International Classification of Diseases, Eleventh Revision (ICD-11), World Health Organization (WHO) 2019/2021. https://icd.who.int/browse11
  2. Falret J. De la folie circulaire ou forme de maladie mentale caracterisée par alternative régulière de la manie et de la melancholie. 1851.
  3. Baillarger JGF. Note sur un genre de folie dont les accè s sont caracté risé s par deux pé riodes réguliè res, l’une de dépression et l’autre d’excitation. Bull Acad Imperiale Med. Séance 31st January 1854.
  4. Kraepelin, E. Manic-depressive Insanity and Paranoia. Translated by R. Mary Barclay from the Eighth German Edition of the «Textbook of Psychiatry», vol. 3 and 4, 1920. New York: Arno Press; 1976.
  5. Swartz HA, Suppes T, American Psychiatric Association Publishing, eds. Bipolar II Disorder: Recognition, Understanding, and Treatment. First edition. American Psychiatric Association Publishing; 2019.
  6. Kukopulos A, Reginaldi D, Laddomada P, et al. Course of the Manic-Depressive Cycle and Changes Caused by Treatments. Pharmacopsychiatry. 2008;13(04):156-167.  https://doi.org/10.1055/s-2007-1019628
  7. Haag H, Heidorn A, Haag M, Greil W. Sequence of affective polarity and lithium response: Preliminary report on munich sample. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1987;11(2-3):205-208.  https://doi.org/10.1016/0278-5846(87)90061-3
  8. Dunner DL, Patrick V, Fieve RR. Rapid cycling manic depressive patients. Comprehensive Psychiatry. 1977;18(6):561-566.  https://doi.org/10.1016/S0010-440X(97)90006-7
  9. Wittenborn JR. Deductive Approaches To The Catecholamine Hypothesis Of Affective Disorders. The Journal of Nervous and Mental Disease. 1974;158(5):320-324.  https://doi.org/10.1097/00005053-197405000-00002
  10. Tissot R. The Common Pathophysiology of Monoaminergic Psychoses: a New Hypothesis. Neuropsychobiology. 1975;1(4):243-260.  https://doi.org/10.1159/000117498
  11. Stockmeier CA. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. Journal of Psychiatric Research. 2003;37(5):357-373.  https://doi.org/10.1016/S0022-3956(03)00050-5
  12. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 1st ed. Cambridge University Press; 2022. https://doi.org/10.1017/9781009053365
  13. Jimerson DC, Post RM, Carman JS, et al. CSF calcium: clinical correlates in affective illness and schizophrenia. Biol Psychiatry. 1979;14(1):37-51. 
  14. Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol. 1984;25(2):228-234. 
  15. Maan JS, Duong T vi H, Saadabadi A. Carbamazepine. In: StatPearls. StatPearls Publishing; 2023. Accessed October 26, 2023. https://www.ncbi.nlm.nih.gov/books/NBK482455/
  16. Casamassima F, Hay AC, Benedetti A, et al. L‐type calcium channels and psychiatric disorders: A brief review. American J of Med Genetics Pt B. 2010;153B(8):1373-1390. https://doi.org/10.1002/ajmg.b.31122
  17. Gareri P, Mattace R, Nava F, De Sarro G. Role of calcium in brain aging. General Pharmacology: The Vascular System. 1995;26(8):1651-1657. https://doi.org/10.1016/0306-3623(95)00043-7
  18. Crammer JL. Calcium metabolism and mental disorder. Psychol Med. 1977;7(4):557-560.  https://doi.org/10.1017/S003329170000619X
  19. Carman JS, Wyatt RJ. Calcium: bivalent cation in the bivalent psychoses. Biol Psychiatry. 1979;14(2):295-336. 
  20. Dubovsky SL. Increased Platelet Intracellular Calcium Concentration in Patients With Bipolar Affective Disorders. Arch Gen Psychiatry. 1989;46(7):632.  https://doi.org/10.1001/archpsyc.1989.01810070058010
  21. Harrison PJ, Hall N, Mould A, Al-Juffali N, Tunbridge EM. Cellular calcium in bipolar disorder: systematic review and meta-analysis. Mol Psychiatry. 2021;26(8):4106-4116. https://doi.org/10.1038/s41380-019-0622-y
  22. Nowycky MC, Fox AP, Tsien RW. Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature. 1985;316(6027):440-443.  https://doi.org/10.1038/316440a0
  23. Little HJ. L-Type Calcium Channel Blockers: A Potential Novel Therapeutic Approach to Drug Dependence. Pharmacol Rev. 2021;73(4):127-154.  https://doi.org/10.1124/pharmrev.120.000245
  24. Herold KG, Hussey JW, Dick IE. CACNA1C-Related Channelopathies. In: Striessnig J, ed. Voltage-Gated Ca2+ Channels: Pharmacology, Modulation and Their Role in Human Disease. Vol 279. Handbook of Experimental Pharmacology. Springer International Publishing; 2023;159-181.  https://doi.org/10.1007/164_2022_624
  25. Kabir ZD, Lee AS, Rajadhyaksha AM. L‐type Ca 2+ channels in mood, cognition and addiction: integrating human and rodent studies with a focus on behavioural endophenotypes. The Journal of Physiology. 2016;594(20):5823-5837. https://doi.org/10.1113/JP270673
  26. Hardingham GE, Chawla S, Johnson CM, Bading H. Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. Nature. 1997;385(6613):260-265.  https://doi.org/10.1038/385260a0
  27. Striessnig J, Koschak A, Sinnegger-Brauns MJ, et al. Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochemical Society Transactions. 2006;34(5):903-909.  https://doi.org/10.1042/BST0340903
  28. Schlecker C, Boehmerle W, Jeromin A, et al. Neuronal calcium sensor-1 enhancement of InsP3 receptor activity is inhibited by therapeutic levels of lithium. J Clin Invest. 2006;116(6):1668-1674. https://doi.org/10.1172/JCI22466
  29. Foskett JK, White C, Cheung KH, Mak DOD. Inositol Trisphosphate Receptor Ca 2+ Release Channels. Physiological Reviews. 2007;87(2):593-658.  https://doi.org/10.1152/physrev.00035.2006
  30. Scriabine A, Van Den Kerckhoff W. Pharmacology of Nimodipine: A Review. Annals of the New York Academy of Sciences. 1988;522(1):698-706.  https://doi.org/10.1111/j.1749-6632.1988.tb33415.x
  31. Goodnick PJ. The use of nimodipine in the treatment of mood disorders: Nimodipine in mood disorders. Bipolar Disorders. 2000;2(3):165-173.  https://doi.org/10.1034/j.1399-5618.2000.020303.x
  32. Caro A, Tarabova B, Rojo-Ruiz J, Lacinova L. Nimodipine inhibits AP firing in cultured hippocampal neurons predominantly due to block of voltage-dependent potassium channels. Gen Physiol Biophys. 2011;30(05):44-53.  https://doi.org/10.4149/gpb_2011_SI1_44
  33. Pazzaglia PJ, Post RM, Ketter TA, et al. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Research. 1993;49(3):257-272.  https://doi.org/10.1016/0165-1781(93)90066-P
  34. Pazzaglia PJ, Post RM, Ketter TA, et al. Nimodipine Monotherapy and Carbamazepine Augmentation in Patients With Refractory Recurrent Affective Illness: Journal of Clinical Psychopharmacology. 1998;18(5):404-413.  https://doi.org/10.1097/00004714-199810000-00009
  35. Goodnick PJ. Nimodipine treatment of rapid cycling bipolar disorder. J Clin Psychiatry. 1995;56(7):330. 
  36. Brunet G, Cerlich B, Robert P, et al. Open Trial of a Calcium Antagonist, Nimodipine, in Acute Mania: Clinical Neuropharmacology. 1990;13(3):224-228.  https://doi.org/10.1097/00002826-199006000-00004
  37. Hesslinger B, Riedel H, Hellwig B, et al. Phase prevention in bipolar affective disorder with nimodipine. A case report. Nervenarzt. 1996;67(5):394-396. 
  38. Manna V. Bipolar affective disorders and role of intraneuronal calcium. Therapeutic effects of the treatment with lithium salts and/or calcium antagonist in patients with rapid polar inversion. Minerva Med. 1991;82(11):757-763. 
  39. Davanzo PA, Krah N, Kleiner J, McCracken J. Nimodipine Treatment of an Adolescent with Ultradian Cycling Bipolar Affective Illness. Journal of Child and Adolescent Psychopharmacology. 1999;9(1):51-61.  https://doi.org/10.1089/cap.1999.9.51
  40. Mallinger AG, Thase ME, Haskett R, et al. Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. Bipolar Disorders. 2008;10(8):856-866.  https://doi.org/10.1111/j.1399-5618.2008.00636.x
  41. Price WA, Shalley JE. Lithium‐Verapamil Toxicity in the Elderly. J American Geriatrics Society. 1987;35(2):177-178.  https://doi.org/10.1111/j.1532-5415.1987.tb01353.x
  42. Helmuth D, Ljaljevic Z, Ramirez L, Meltzer HY. Choreoathetosis induced by verapamil and lithium treatment. J Clin Psychopharmacol. 1989;9(6):454-455. 
  43. Dubovsky SL, Franks RD, Allen S. Verapamil: a new antimanic drug with potential interactions with lithium. J Clin Psychiatry. 1987;48(9):371-372. 
  44. Price WA, Giannini AJ. Neurotoxicity Caused by Lithium‐Verapamil Synergism. The Journal of Clinical Pharma. 1986;26(8):717-719.  https://doi.org/10.1002/j.1552-4604.1986.tb02980.x
  45. Cipriani A, Saunders K, Attenburrow MJ, et al. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Mol Psychiatry. 2016;21(10):1324-1332. https://doi.org/10.1038/mp.2016.86
  46. Caillard V. Treatment of Mania Using a Calcium Antagonist — Preliminary Trial. Neuropsychobiology. 1985;14(1):23-26.  https://doi.org/10.1159/000118196
  47. Dose M, Emrich HM, Cording-Tömmel C, Von Zerssen D. Use of calcium antagonists in mania. Psychoneuroendocrinology. 1986;11(2):241-243.  https://doi.org/10.1016/0306-4530(86)90060-0
  48. Silverstone PH, Birkett L. Diltiazem as augmentation therapy in patients with treatment-resistant bipolar disorder: a retrospective study. J Psychiatry Neurosci. 2000;25(3):276-280. 
  49. Ostacher MJ, Iosifescu DV, Hay A, et al. Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome‐wide association. Bipolar Disorders. 2014;16(2):199-203.  https://doi.org/10.1111/bdi.12143
  50. Taragano FE, Allegri R, Vicario A, et al. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of ?vascular depression? Int J Geriat Psychiatry. 2001;16(3):254-260.  https://doi.org/10.1002/gps.340
  51. Liu J, Sun C, Wang Y, et al. Efficacy of nimodipine in the treatment of subarachnoid hemorrhage: a meta-analysis. Arq Neuropsiquiatr. 2022;80(07):663-670.  https://doi.org/10.1055/s-0042-1755301
  52. Rossiiskoe obshchestvo psikhiatrov «Klinicheskie rekomendatsii Bipolyarnoe affektivnoe rasstroistvo» 2022. (In Russ.).

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.